Amgen (AMGN) Stock Forecast & Price Target

Compare

6,522 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AMGN Analyst Ratings

Moderate Buy

11 Buy

10 Hold

1 Sell

Based on 22 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AMGN Stock 12 Month Forecast

Average Price Target

$326.76

▲(10.08%Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $326.76 with a high forecast of $400.00 and a low forecast of $252.00. The average price target represents a 10.08% change from the last price of $296.85.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"251":"$251","326":"$326","401":"$401","288.5":"$288.5","363.5":"$363.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":400,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$400.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":326.76,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$326.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":252,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$252.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[251,288.5,326,363.5,401],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,290.52,298.94153846153847,307.3630769230769,315.7846153846154,324.2061538461538,332.6276923076923,341.04923076923075,349.47076923076924,357.89230769230767,366.31384615384616,374.7353846153846,383.1569230769231,391.5784615384615,{"y":400,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,290.52,293.30769230769226,296.0953846153846,298.8830769230769,301.6707692307692,304.4584615384615,307.24615384615385,310.0338461538461,312.82153846153847,315.60923076923075,318.3969230769231,321.18461538461537,323.9723076923077,{"y":326.76,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,290.52,287.55692307692306,284.59384615384613,281.6307692307692,278.6676923076923,275.70461538461535,272.7415384615384,269.77846153846156,266.81538461538463,263.8523076923077,260.8892307692308,257.92615384615385,254.96307692307693,{"y":252,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":301.29,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.04,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.65,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":312.47,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":311.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":273.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":280.65,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":305.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":304.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":281.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":288.47,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":290.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$400.00

Average Price Target$326.76

Lowest Price Target$252.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$324

Buy

9.15%

Upside

Reiterated

07/02/25

Amgen's strong financial performance and positive earnings call highlight its strengths in profitability and growth potential. While technical indicators are less favorable, and high leverage poses some risk, the company's strategic investments and robust cash flow provide a solid foundation for long-term growth.

David AmsellemPiper Sandler

Piper Sandler

$328

Buy

10.49%

Upside

Reiterated

07/01/25

Piper Sandler Sticks to Their Buy Rating for Amgen (AMGN)

Yaron WerberTD Cowen

TD Cowen

$389

Buy

31.04%

Upside

Reiterated

06/30/25

Amgen (AMGN) Receives a Buy from TD Cowen

Terence FlynnMorgan Stanley

Morgan Stanley

$330

Hold

11.17%

Upside

Reiterated

06/30/25

Hold Rating on Amgen: Limited Market Opportunity and Safety Concerns for Bemarituzumab Despite Positive Trial Results

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

06/30/25

Amgen's Promising Clinical Trial Results Justify Buy Rating Despite Adverse Event Concerns

David RisingerLeerink Partners

Leerink Partners

―

Hold

―

Reiterated

06/24/25

Amgen's Cautious Progress and Long-Term Strategy Justifies Hold Rating

Salveen RichterGoldman Sachs

Goldman Sachs

$400

Buy

34.75%

Upside

Reiterated

06/24/25

Amgen's MariTide Shows Promising Efficacy and Expanding Applications, Leading to Buy Recommendation

Vamil DivanGuggenheim

Guggenheim

$288

Hold

-2.98%

Downside

Reiterated

06/24/25

Guggenheim Remains a Hold on Amgen (AMGN)

Evan SeigermanBMO Capital

BMO Capital

$346

Buy

16.56%

Upside

Reiterated

06/24/25

Amgen (AMGN) Gets a Buy from BMO Capital

Mohit BansalWells Fargo

Wells Fargo

$280

Hold

-5.68%

Downside

Reiterated

06/24/25

Wells Fargo Remains a Hold on Amgen (AMGN)We rate AMGN Equal Weight as we think the company's near- to medium-term growth profile is limited with MariTide's potential Ph2 success already largely priced in to shares.

Carter GouldCantor Fitzgerald

Cantor Fitzgerald

$305

Hold

2.75%

Upside

Reiterated

06/24/25

Cantor Fitzgerald Sticks to Their Hold Rating for Amgen (AMGN)

Geoff MeachamCiti

Citi

$290→$300

Hold

1.06%

Upside

Reiterated

06/24/25

Amgen's Stock Faces Pressure Amid Safety Concerns with MariTide: Hold Rating Maintained

Umer RaffatEvercore ISI

Evercore ISI

―

Buy

―

Reiterated

06/24/25

Amgen (AMGN) Receives a Buy from Evercore ISI

Srikripa DevarakondaTruist Financial

Truist Financial

―

Hold

―

Reiterated

06/24/25

Truist Financial Sticks to Their Hold Rating for Amgen (AMGN)

Tim AndersonBank of America Securities

Bank of America Securities

$252

Sell

-15.11%

Downside

Reiterated

06/23/25

Sell Rating for Amgen Amid Concerns Over MariTide Trials and Market Positioning

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$324

Buy

9.15%

Upside

Reiterated

07/02/25

David AmsellemPiper Sandler

Piper Sandler

$328

Buy

10.49%

Upside

Reiterated

07/01/25

Piper Sandler Sticks to Their Buy Rating for Amgen (AMGN)

Yaron WerberTD Cowen

TD Cowen

$389

Buy

31.04%

Upside

Reiterated

06/30/25

Amgen (AMGN) Receives a Buy from TD Cowen

Terence FlynnMorgan Stanley

Morgan Stanley

$330

Hold

11.17%

Upside

Reiterated

06/30/25

Hold Rating on Amgen: Limited Market Opportunity and Safety Concerns for Bemarituzumab Despite Positive Trial Results

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

06/30/25

Amgen's Promising Clinical Trial Results Justify Buy Rating Despite Adverse Event Concerns

David RisingerLeerink Partners

Leerink Partners

―

Hold

―

Reiterated

06/24/25

Amgen's Cautious Progress and Long-Term Strategy Justifies Hold Rating

Salveen RichterGoldman Sachs

Goldman Sachs

$400

Buy

34.75%

Upside

Reiterated

06/24/25

Amgen's MariTide Shows Promising Efficacy and Expanding Applications, Leading to Buy Recommendation

Vamil DivanGuggenheim

Guggenheim

$288

Hold

-2.98%

Downside

Reiterated

06/24/25

Guggenheim Remains a Hold on Amgen (AMGN)

Evan SeigermanBMO Capital

BMO Capital

$346

Buy

16.56%

Upside

Reiterated

06/24/25

Amgen (AMGN) Gets a Buy from BMO Capital

Mohit BansalWells Fargo

Wells Fargo

$280

Hold

-5.68%

Downside

Reiterated

06/24/25

Carter GouldCantor Fitzgerald

Cantor Fitzgerald

$305

Hold

2.75%

Upside

Reiterated

06/24/25

Cantor Fitzgerald Sticks to Their Hold Rating for Amgen (AMGN)

Geoff MeachamCiti

Citi

$290→$300

Hold

1.06%

Upside

Reiterated

06/24/25

Amgen's Stock Faces Pressure Amid Safety Concerns with MariTide: Hold Rating Maintained

Umer RaffatEvercore ISI

Evercore ISI

―

Buy

―

Reiterated

06/24/25

Amgen (AMGN) Receives a Buy from Evercore ISI

Srikripa DevarakondaTruist Financial

Truist Financial

―

Hold

―

Reiterated

06/24/25

Truist Financial Sticks to Their Hold Rating for Amgen (AMGN)

Tim AndersonBank of America Securities

Bank of America Securities

$252

Sell

-15.11%

Downside

Reiterated

06/23/25

Sell Rating for Amgen Amid Concerns Over MariTide Trials and Market Positioning

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

1 Month

xxx

Success Rate

15/29 ratings generated profit

Average Return

-0.50%

assigned a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 51.72% of your transactions generating a profit, with an average return of -0.50% per trade.

3 Months

xxx

Success Rate

21/34 ratings generated profit

Average Return

+2.31%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.76% of your transactions generating a profit, with an average return of +2.31% per trade.

1 Year

Yaron WerberTD Cowen

Success Rate

28/38 ratings generated profit

Average Return

+12.02%

reiterated a buy rating 4 days ago

Copying Yaron Werber's trades and holding each position for 1 Year would result in 73.68% of your transactions generating a profit, with an average return of +12.02% per trade.

2 Years

xxx

Success Rate

28/34 ratings generated profit

Average Return

+13.85%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 82.35% of your transactions generating a profit, with an average return of +13.85% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMGN Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AMGN has received 26 Buy Ratings, 19 Hold Ratings, and 4 Sell Ratings. AMGN average Analyst price target in the past 3 months is 326.76.

Each month's total comprises the sum of three months' worth of ratings.

AMGN Financial Forecast

AMGN Earnings Forecast

Next quarter’s earnings estimate for AMGN is $5.23 with a range of $4.81 to $5.84. The previous quarter’s EPS was $4.90. AMGN beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year AMGN has Outperformed its overall industry.

AMGN Sales Forecast

Next quarter’s sales forecast for AMGN is $8.88B with a range of $8.60B to $9.20B. The previous quarter’s sales results were $8.09B. AMGN beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year AMGN has Outperformed its overall industry.

AMGN Stock Forecast FAQ

What is AMGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen’s 12-month average price target is 326.76.

What is AMGN’s upside potential, based on the analysts’ average price target?

Amgen has 10.08% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AMGN a Buy, Sell or Hold?

Amgen has a consensus rating of Moderate Buy which is based on 11 buy ratings, 10 hold ratings and 1 sell ratings.

What is Amgen’s price target?

The average price target for Amgen is 326.76. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $400.00 ,the lowest forecast is $252.00. The average price target represents 10.08% Increase from the current price of $296.85.

What do analysts say about Amgen?

Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of AMGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Amgen (AMGN) Stock Forecast & Price Target

AMGN Analyst Ratings

AMGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

AMGN Analyst Recommendation Trends

AMGN Financial Forecast

AMGN Earnings Forecast

AMGN Sales Forecast

AMGN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts